Evaluation of the NanoCHIP® Infection Control Panel test for direct detection and screening of methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria and vancomycin-resistant Enterococcus (VRE).
Rapid detection of infection control targets is needed and several bacterial target assays are commercially available. Detection of patients colonized with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae (KPC-CRE), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) comprises an essential part of infection control programs. This study evaluated the performance and feasibility of a novel molecular-based diagnostic screening test, the NanoCHIP(®) Infection Control Panel (ICP) assay (Savyon Diagnostics, Israel), which enables simultaneous detection of KPC-CRE, MRSA and VRE directly from swab samples and compares its sensitivity and specificity to culture. Prospective direct swab analysis of 338 (70 CRE, 198 MRSA and 70 VRE) screening swab samples. Including all targets and all valid samples, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the NanoCHIP(®) ICP assay were 91.1, 99.5, 99.1 and 94.9 %, respectively. As far as we know, this is the first report regarding a single molecular-based system that detects all three targets (CRE-KPC, MRSA and VRE) simultaneously, directly from swab samples, using the same reaction and platform. Overall, the assay was easy to perform, enabling medium- to high-throughput screening. Same day results enable efficient infection control interventions, such as carrier isolation.